Introduction: A Paradigm Shift in Heart Failure Care
In the landscape of chronic disease management, few challenges are as persistent or as resource-intensive as the treatment of oedema in heart failure patients. Fluid retention, caused by the heart’s inability to pump efficiently, leads to swelling in the ankles, legs, and feet, necessitating frequent, costly, and disruptive hospital admissions. However, a significant breakthrough presented at the 2026 Heart Failure Congress in Barcelona suggests that the paradigm of care is shifting.
SQ Innovation has unveiled compelling topline data from its SUBCUT HF II study, demonstrating that its drug-device combination, Lasix Onyu, successfully facilitates the management of oedema at home. By enabling patients to bypass traditional intravenous (IV) hospital treatment without sacrificing clinical efficacy, this innovation promises to reshape the patient experience and alleviate the mounting pressure on global healthcare infrastructure.
The Clinical Challenge: Why Oedema Matters
Oedema is more than a symptom; it is a clinical manifestation of a failing circulatory system. When the heart’s pumping efficiency falters, blood flow slows, causing fluid to pool in the veins. This hydrostatic pressure forces fluid into surrounding tissues, resulting in the characteristic swelling that defines peripheral oedema.
For the millions living with chronic heart failure, this cycle of fluid accumulation often leads to "decompensation," where the patient becomes symptomatic and requires urgent medical intervention. Traditionally, this intervention has required a hospital stay for the administration of intravenous diuretics—the gold standard of care for decades. These admissions are not only burdensome for the patient, who faces the stress and risk of hospital-acquired complications, but they also occupy critical beds in an already overburdened hospital system.
Chronology of Development: From Concept to Clinical Validation
The path to Lasix Onyu’s market presence has been a methodical journey of regulatory milestones and clinical rigor.
- December 2024: SQ Innovation reached its first major regulatory hurdle, receiving "tentative" approval from the US Food and Drug Administration (FDA). This signaled the agency’s confidence in the safety and manufacturing profile of the device, even as further clinical validation was pending.
- October 2025: Following the successful resolution of outstanding requirements, the FDA granted full approval for Lasix Onyu. This green light paved the way for widespread clinical integration.
- May 2026: At the European Society of Cardiology’s (ESC) Heart Failure 2026 congress in Barcelona, SQ Innovation presented the definitive data from its SUBCUT HF II (NCT05419115) study. This presentation served as the final validation of the device’s real-world utility compared to the standard-of-care (SoC) hospital treatment.
Supporting Data: The SUBCUT HF II Results
The SUBCUT HF II trial was designed to rigorously test the non-inferiority and practical advantages of the Lasix Onyu system against traditional IV diuretics. The study enrolled 172 patients, who were randomized into two distinct cohorts: 92 patients received at-home treatment via the Lasix Onyu system, while 80 patients served as the control group, undergoing standard-of-care treatment in a hospital setting.
Primary Endpoint Success
The study’s primary endpoint was the avoidance of at least 3.5 days of inpatient care. The results were striking: patients treated with Lasix Onyu at home spent an average of four fewer days in the hospital compared to those receiving traditional IV furosemide. This not only met the primary endpoint but exceeded expectations for patient outcomes regarding time spent away from clinical wards.
Safety and Efficacy
Beyond the reduction in hospital days, the secondary endpoints confirmed that at-home treatment provided clinical outcomes equivalent to those achieved in the hospital. Crucially, the safety profile was favorable. Adverse events (AEs) were infrequent across both groups, and, significantly, there were zero device-related serious adverse events. This safety record is pivotal for home-use devices, where the oversight of a clinical team is necessarily reduced compared to an acute care unit.
Technological Innovation: The Mechanics of Lasix Onyu
Lasix Onyu is a sophisticated synthesis of pharmacology and engineering. The system is composed of two primary elements:
- The High-Concentration Formulation: The drug component utilizes a specialized, high-concentration formulation of the diuretic furosemide, optimized for subcutaneous delivery rather than traditional IV administration.
- The Delivery System: The device itself is an on-body, cartridge-based infuser. It features automated needle insertion and retraction, minimizing user error and pain. The system is designed with a reusable electromechanical component—capable of supporting up to 48 treatments—and a single-use sterile disposable component that handles the drug solution.
This modular design ensures that the device is both economically sustainable and user-friendly, allowing patients or their caregivers to manage fluid retention without specialized medical training.
Official Responses and Clinical Perspectives
The medical community has greeted the data with a mixture of relief and enthusiasm. Professor Mark Petrie of the Glasgow Cardiovascular Research Centre at the University of Glasgow, who served as a principal investigator for the SUBCUT HF II study, highlighted the historical context of this advancement.
"Oedema in heart failure is a leading reason for hospital admissions worldwide," Prof. Petrie stated. "This novel treatment option relies on the same therapeutic fundamentals that have been in place in the hospital since the 1960s. Enabling this to now be done at home by a patient or caregiver fundamentally changes the nature and trajectory of this very common and burdensome disorder."
By modernizing the delivery of a long-standing, effective therapy, SQ Innovation has managed to bridge the gap between legacy medicine and 21st-century patient-centric care.
Implications: The Future of Heart Failure Management
For the Patient
The shift to home-based care offers a profound improvement in quality of life. Hospitalization for heart failure is often associated with a decline in functional status and a psychological toll. By treating oedema at home, patients can maintain their daily routines, avoid the risks of hospital-acquired infections, and experience greater autonomy over their condition.
For Healthcare Systems
The economic implications are equally significant. Hospital beds are the most expensive resource in any healthcare system. By reducing the average stay by four days per treatment cycle, hospitals can free up capacity for more acute surgical or diagnostic cases. Furthermore, as healthcare systems move toward "value-based care" models, the ability to demonstrate reduced hospital readmission rates becomes a vital metric for reimbursement and operational efficiency.
Future Research and Expansion
While the SUBCUT HF II study focused on the avoidance of hospital days, the broader impact of Lasix Onyu will likely be seen in longitudinal studies regarding long-term patient survival and heart failure progression. As the medical community adopts this technology, researchers will likely look into whether earlier intervention at home—before a patient requires hospitalization—could lead to even better long-term prognosis.
Conclusion
The data presented at the 2026 Heart Failure Congress marks a turning point for patients living with chronic heart failure. SQ Innovation’s Lasix Onyu has demonstrated that the standard of care no longer needs to be synonymous with the four walls of a hospital. By combining the proven efficacy of furosemide with a user-friendly, high-tech delivery device, the company has provided a scalable solution to one of the most persistent burdens in cardiovascular medicine. As healthcare continues to decentralize, the success of the SUBCUT HF II study serves as a blueprint for how innovation can reconcile the needs of patients with the logistical demands of modern medicine.
About the Author
